Latest News and Press Releases

Rockville, MD, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The global Clostridium difficile infection treatment market has been estimated at US$ 1.24 billion for 2024 and is projected to expand at a CAGR of...

C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. alone U.S. Patent Office issues...

DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...

Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...

Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...

BEVERLY HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination and infection prevention company that specializes in...

Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid  Single dose randomized trial...

AMSTERDAM, Netherlands, April 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented data from two pre-clinical studies evaluating the impact of omadacycline on...

Patients with C. diff stay in hospital 55 percent longer and are 77 percent more likely to be readmitted CHARLOTTE, N.C., Dec. 10, 2015 (GLOBE NEWSWIRE) --  Clostridium difficile (C. diff),...

BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...